| 22.07 -0.9 (-3.92%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 27.19 |
1-year : | 28.07 |
| Resists | First : | 23.28 |
Second : | 24.04 |
| Pivot price | 22.65 |
|||
| Supports | First : | 22.05 |
Second : | 18.35 |
| MAs | MA(5) : | 22.64 |
MA(20) : | 22.85 |
| MA(100) : | 22.88  |
MA(250) : | 22.95 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 35 |
D(3) : | 40.1 |
| RSI | RSI(14): 34.2 |
|||
| 52-week | High : | 26.56 | Low : | 19.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FMS ] has closed above bottom band by 5.4%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.71 - 22.83 | 22.83 - 22.9 |
| Low: | 21.79 - 21.94 | 21.94 - 22.04 |
| Close: | 21.85 - 22.08 | 22.08 - 22.23 |
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Thu, 17 Sep 2026
FMC stock gains as UBS and Barclays highlight upside potential - ad-hoc-news.de
Thu, 17 Sep 2026
Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS - marketbeat.com
Mon, 14 Sep 2026
Fresenius Medical Care AG (FMS) Stock Analysis: Navigating a 14.82% Potential Upside in the Healthcare Sector - directorstalkinterviews.com
Thu, 03 Sep 2026
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase? - Yahoo Finance
Tue, 04 Aug 2026
Fresenius Medical Slumps on Dialysis Growth Concerns - Bloomberg.com
Mon, 03 Aug 2026
Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 532 (M) |
| Shares Float | 397 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 2,670 (K) |
| Shares Short P.Month | 2,680 (K) |
| EPS | 1.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 27.48 |
| Profit Margin | 4.8 % |
| Operating Margin | 10.7 % |
| Return on Assets (ttm) | 3.9 % |
| Return on Equity (ttm) | 8.5 % |
| Qtrly Rev. Growth | 1.3 % |
| Gross Profit (p.s.) | 9.62 |
| Sales Per Share | 36.5 |
| EBITDA (p.s.) | 5.11 |
| Qtrly Earnings Growth | 5.5 % |
| Operating Cash Flow | 2,830 (M) |
| Levered Free Cash Flow | 2,020 (M) |
| PE Ratio | 11.49 |
| PEG Ratio | 0.7 |
| Price to Book value | 0.8 |
| Price to Sales | 0.6 |
| Price to Cash Flow | 4.15 |
| Dividend | 0.87 |
| Forward Dividend | 0 |
| Dividend Yield | 3.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|